Skip to main content
NCBI home page
Gut logoLink to Gut
. 1987 Feb;28(2):113–116. doi: 10.1136/gut.28.2.113

Immunotherapy for cancer: the use of lymphokine activated killer (LAK) cells.

E A Fagan, A L Eddleston
PMCID: PMC1432985  PMID: 3549471

Full text

PDF
113

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Borberg H., Oettgen H. F., Choudry K., Beattie E. J., Jr Inhibition of established transplants of chemically induced sarcomas in syngeneic mice by lymphocytes from immunized donors. Int J Cancer. 1972 Nov;10(3):539–547. doi: 10.1002/ijc.2910100312. [DOI] [PubMed] [Google Scholar]
  2. Donohue J. H., Rosenberg S. A. The fate of interleukin-2 after in vivo administration. J Immunol. 1983 May;130(5):2203–2208. [PubMed] [Google Scholar]
  3. Grimm E. A., Mazumder A., Zhang H. Z., Rosenberg S. A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982 Jun 1;155(6):1823–1841. doi: 10.1084/jem.155.6.1823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Grimm E. A., Ramsey K. M., Mazumder A., Wilson D. J., Djeu J. Y., Rosenberg S. A. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J Exp Med. 1983 Mar 1;157(3):884–897. doi: 10.1084/jem.157.3.884. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hsieh K. H., Shu S. Y., Lee C. S., Chu C. T., Yang C. S., Chang K. J. Lysis of primary hepatic tumours by lymphokine activated killer cells. Gut. 1987 Feb;28(2):117–124. doi: 10.1136/gut.28.2.117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Itoh K., Tilden A. B., Kumagai K., Balch C. M. Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells. J Immunol. 1985 Feb;134(2):802–807. [PubMed] [Google Scholar]
  7. Lafreniere R., Rosenberg S. A. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res. 1985 Aug;45(8):3735–3741. [PubMed] [Google Scholar]
  8. Lanier L. L., Benike C. J., Phillips J. H., Engleman E. G. Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens. J Immunol. 1985 Feb;134(2):794–801. [PubMed] [Google Scholar]
  9. Lotze M. T., Grimm E. A., Mazumder A., Strausser J. L., Rosenberg S. A. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res. 1981 Nov;41(11 Pt 1):4420–4425. [PubMed] [Google Scholar]
  10. Lotze M. T., Line B. R., Mathisen D. J., Rosenberg S. A. The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors. J Immunol. 1980 Oct;125(4):1487–1493. [PubMed] [Google Scholar]
  11. Lotze M. T., Matory Y. L., Ettinghausen S. E., Rayner A. A., Sharrow S. O., Seipp C. A., Custer M. C., Rosenberg S. A. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol. 1985 Oct;135(4):2865–2875. [PubMed] [Google Scholar]
  12. Lotze M. T., Robb R. J., Sharrow S. O., Frana L. W., Rosenberg S. A. Systemic administration of interleukin-2 in humans. J Biol Response Mod. 1984 Oct;3(5):475–482. [PubMed] [Google Scholar]
  13. Matory Y. L., Chang A. E., Lipford E. H., 3rd, Braziel R., Hyatt C. L., McDonald H. D., Rosenberg S. A. Toxicity of recombinant human interleukin-2 in rats following intravenous infusion. J Biol Response Mod. 1985 Aug;4(4):377–390. [PubMed] [Google Scholar]
  14. Mazumder A., Eberlein T. J., Grimm E. A., Wilson D. J., Keenan A. M., Aamodt R., Rosenberg S. A. Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells. Cancer. 1984 Feb 15;53(4):896–905. doi: 10.1002/1097-0142(19840215)53:4<896::aid-cncr2820530414>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  15. Mulé J. J., Rosenstein M., Shu S., Rosenberg S. A. Eradication of a disseminated syngeneic mouse lymphoma by systemic adoptive transfer of immune lymphocytes and its dependence upon a host component(s). Cancer Res. 1985 Feb;45(2):526–531. [PubMed] [Google Scholar]
  16. Mulé J. J., Shu S., Rosenberg S. A. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. J Immunol. 1985 Jul;135(1):646–652. [PubMed] [Google Scholar]
  17. Okuno K., Takagi H., Nakamura T., Nakamura Y., Iwasa Z., Yasutomi M. Treatment for unresectable hepatoma via selective hepatic arterial infusion of lymphokine-activated killer cells generated from autologous spleen cells. Cancer. 1986 Sep 1;58(5):1001–1006. doi: 10.1002/1097-0142(19860901)58:5<1001::aid-cncr2820580502>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  18. Phillips J. H., Lanier L. L. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med. 1986 Sep 1;164(3):814–825. doi: 10.1084/jem.164.3.814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Rosenberg S. A. Adoptive immunotherapy of cancer: accomplishments and prospects. Cancer Treat Rep. 1984 Jan;68(1):233–255. [PubMed] [Google Scholar]
  20. Rosenberg S. A., Grimm E. A., McGrogan M., Doyle M., Kawasaki E., Koths K., Mark D. F. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science. 1984 Mar 30;223(4643):1412–1414. doi: 10.1126/science.6367046. [DOI] [PubMed] [Google Scholar]
  21. Rosenberg S. A. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2. J Biol Response Mod. 1984 Oct;3(5):501–511. [PubMed] [Google Scholar]
  22. Rosenberg S. A., Lotze M. T., Muul L. M., Leitman S., Chang A. E., Ettinghausen S. E., Matory Y. L., Skibber J. M., Shiloni E., Vetto J. T. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985 Dec 5;313(23):1485–1492. doi: 10.1056/NEJM198512053132327. [DOI] [PubMed] [Google Scholar]
  23. Rosenberg S. A., Spiess P., Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986 Sep 19;233(4770):1318–1321. doi: 10.1126/science.3489291. [DOI] [PubMed] [Google Scholar]
  24. Smith H. G., Harmel R. P., Hanna M. G., Jr, Zwilling B. S., Zbar B., Rapp H. J. Regression of established intradermal tumors and lymph node metastases in guinea pigs after systemic transfer of immune lymphoid cells. J Natl Cancer Inst. 1977 May;58(5):1315–1322. doi: 10.1093/jnci/58.5.1315. [DOI] [PubMed] [Google Scholar]
  25. Taniguchi T., Matsui H., Fujita T., Takaoka C., Kashima N., Yoshimoto R., Hamuro J. Structure and expression of a cloned cDNA for human interleukin-2. Nature. 1983 Mar 24;302(5906):305–310. doi: 10.1038/302305a0. [DOI] [PubMed] [Google Scholar]
  26. Yron I., Wood T. A., Jr, Spiess P. J., Rosenberg S. A. In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J Immunol. 1980 Jul;125(1):238–245. [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES